Experienced in Teratoma of the Mediastinum

Vsevolod B. Matveev

Federal State Budgetary Institution оF The Ministry Of Health Of The Russian Federation
Moscow, MOW, RU 
Experienced in Teratoma of the Mediastinum
Federal State Budgetary Institution оF The Ministry Of Health Of The Russian Federation
Moscow, MOW, RU 
OverviewLocationsClinical Research

Overview

Vsevolod Matveev practices in Moscow, Russian Federation. Mr. Matveev is rated as an Experienced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Renal Cell Carcinoma (RCC), Penile Cancer, Prostate Cancer, Orchiectomy, and Prostatectomy.

His clinical research consists of co-authoring 336 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

Federal State Budgetary Institution оf the Ministry of Health of the Russian Federation
Moscow, MOW, Russian Federation
Other Locations
Dubna, KLU, Russian Federation
Russian Federation
Gatchina, SMO, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Enrollment Status: Completed
Publish Date: September 20, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

336 Total Publications

Measurement of WWZ and ZH Production Cross Sections at sqrt[s]=13 and 13.6 TeV.
Measurement of WWZ and ZH Production Cross Sections at sqrt[s]=13 and 13.6 TeV.
Journal: Physical review letters
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Matveev's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile